BioArctic AB (publ)
Research BioArctic AB (publ) (BIOA-B) on Bullrun: market cap SEK 28.57B, P/E 135.3, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOA-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 28.57B
- P/E135.3
- Dividend yield0.6%
- Financial periodQ1 2026
- RevenueSEK 437.59M
- Net incomeSEK 212.39M
- Free cash flow-SEK 166.00M
- Gross margin95.5%
Valuation Snapshot
latest market cap is SEK 28.57B; P/E is 135.3; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 135.29x versus a Healthcare sector median of 24.46x (453.1% above).
Latest dividend yield is 0.6% versus a Healthcare sector median of 2.11% (71.6% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 2.00B | SEK 1.02B | SEK 1.43B | 97.0% | 11.54 | SEK 1.04B | SEK 44.07M | SEK 1.97B |
| FY2024 | SEK 257.35M | -SEK 228.52M | n/a | 89.5% | -200000 | SEK 512.93M | SEK 54.23M | SEK 894.94M |
| FY2023 | SEK 616.00M | SEK 252.64M | n/a | 97.6% | 259000 | SEK 611.57M | n/a | SEK 1.05B |
| FY2022 | SEK 228.29M | -SEK 17.34M | n/a | n/a | -13 | SEK 805.39M | n/a | SEK 786.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | SEK 28.57B | 135.3 | 0.6% | 2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2 SEK, yield 0.6%.
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioArctic AB (publ)'s market cap?
BioArctic AB (publ)'s market capitalization is SEK 28.57B.
What is BioArctic AB (publ)'s P/E ratio?
BioArctic AB (publ)'s price-to-earnings (P/E) ratio is 135.3.
Does BioArctic AB (publ) pay a dividend?
BioArctic AB (publ) has a dividend yield of 0.6%.
What does BioArctic AB (publ) do?
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment.